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Background/aim: Tumour necrosis factor inhibitors and anti-interleukin-6 (anti-IL-6) therapies are increasingly being used in
Takayasu’s arteritis (TA) patients who are unresponsive to corticosteroids ± conventional immunosuppressive agents. The aim of this
study is to assess the efficacy and safety of anti-IL-6 (tocilizumab) therapy in refractory TA patients in real life.
Materials and methods: Fifteen TA patients (86.7% were female) who received at least 3 cycles of tocilizumab therapy were retrospectively
assessed by clinical, laboratory, and radiological evaluations before and after tocilizumab therapy.
Results: The median (min–max) age of the patients at evaluation was 35 (20–58) years and the median disease duration from diagnosis
was 24 (12–168) months. The median (min.–max.) duration of follow-up after tocilizumab was 15 (3–42) months. There was a significant
decrease in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and patient global visual analogue scale (VAS) scores of
patients after tocilizumab therapy. The median (min.–max.) ESR was 26 (5–119) vs. 3 (2–49) mm/h, P = 0.02; CRP was 39.8 (2.4–149.0)
vs. 7.9 (0–92.9) mg/L, P = 0.017; and patient global VAS was 50 (0–90) vs. 30 (0–60), P = 0.027, respectively. In 8 patients, ESR and CRP
levels were in the normal range in the last control. Imaging modality results after tocilizumab were available for 9 patients; 8 patients
were radiologically stable and regression was seen in 1 patient. Comparable imaging modality results before and after tocilizumab were
available for 5 patients; 4 patients were radiologically stable and regression was seen in 1 patient. Radiological findings were consistent
with laboratory responses. Glucocorticoid dosages decreased from a mean dosage of 16.2 (9.1) mg/day at baseline to 7.1 (3.8) mg/day (P
= 0.001) at the last follow-up visit. There was no increase in the steroid dosage in any of the patients. All patients tolerated tocilizumab
well.
Conclusion: Based on retrospective real life data, anti-IL-6 (tocilizumab) appears to be an effective and tolerable treatment option in
refractory TA patients.
Key words: Anti-interleukin-6, tocilizumab, Takayasu’s arteritis

1. Introduction
Takayasu’s arteritis (TA) is a rare chronic, inflammatory,
and granulomatous type of large vessel vasculitis that
predominantly affects the aorta and its main branches [1].
Although high-dose glucocorticoids are the cornerstone
of the medical therapy, almost half of the patients need
immunosuppressive agents due to relapses or resistance to
glucocorticoids. The combinations of glucocorticoids with
conventional immunosuppressive agents (methotrexate,
azathioprine, mycophenolate mofetil, and leflunomide)
may lead to a better response and disease control.
However, clinical relapses and progression of vascular
involvement remain frequent [2]. Biological therapies like
TNF inhibitors (TNF-i) and anti-interleukin-6 (anti-IL-6)
therapies may be effective in TA patients with uncontrolled

disease [3]. IL-6, which is shown to be expressed in TA
arterial lesions, influences the function of many types
of cells and has a role in vascular inflammation [4–6].
The preliminary studies and case reports suggested that
tocilizumab, a humanized anti-IL-6 receptor antibody,
may be an option for refractory TA patients [7–15]. The
aim of this retrospective observational study is to assess
the efficacy and safety of tocilizumab in refractory TA
patients in real life.
2. Materials and methods
2.1. Study population
In the prospective database of the Vasculitis Centre of
Hacettepe University (HUVAC), 105 TA patients meeting
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the 1990 modified American College of Rheumatology
(ACR) criteria were registered by the end of July 2017.
Totally, 28 (26.7%) patients received biological therapies
and 22 (21.0%) of them were treated with tocilizumab.
After reviewing the charts of these patients, 7 were excluded
(2 patients had fewer than 3 cycles of tocilizumab infusion,
3 patients had no follow-up data, and 2 patients were
referred to our centre after the initiation of tocilizumab).
Overall, 15 TA patients who received at least 3 doses of
monthly tocilizumab infusions and had available followup data were included. All included patients were treated
with tocilizumab at 8 mg/kg intravenously every 4 weeks.
2.2. Demographic and clinical features
Demographic and clinical characteristics of the patients,
acute phase reactants (erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP)), and visual analogue
scale (VAS) scores for pain, fatigue, and patient global
assessments were recorded at the initiation of tocilizumab
therapy and at the last follow-up visit. Increased acute
phase reactants were defined as ESR of >25 mm in the
first hour by the Westergren method and/or CRP of >8
mg/L. A Likert scale of 0–100 mm was used for assessing
VAS scores (pain, fatigue, patient global assessments).
The data regarding prior and current immunosuppressive
agents and concomitant glucocorticoids accompanying
tocilizumab therapy were also recorded. In our cohort,
some patients received alternate day prednisone (or its
equivalent). Therefore, glucocorticoid dosages of patients
were calculated according to the daily dosage of prednisone
(or its equivalent). Available computed tomography
angiography (CTA) and/or magnetic resonance
angiography (MRA) results of the patients within the 3
months prior to tocilizumab initiation and during followup were obtained from the hospital data system. According
to the angiographic findings, TA patients were classified
into 5 categories [16].
2.3. Laboratory and radiological evaluations
Patients’ clinical, laboratory, and radiological data and
treatments were analysed at baseline (at the initiation of
tocilizumab) and the last follow-up visit. The radiological
evidence of new areas of vessel involvement or worsened
vascular lesions was considered as an ‘active’ disease.
The radiological disease activity was classified as stable
disease (absence of any change in lesions), progression
(development of a new lesion: vessel wall thickening/
irregularity, stenosis, occlusion, aneurysm, and dilatation),
and regression (decline in existing lesions). Patients were
considered to have ‘clinically active’ disease if they had
persistence or exacerbation of the clinical symptoms
and elevated inflammatory laboratory markers despite
unchanged angiographic findings. The adverse events
attributable to tocilizumab, such as infusion reactions,
infections requiring hospitalization, elevated liver
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enzymes, hypertriglyceridemia, and leukopenia, were
checked for safety assessment.
2.4. Ethical considerations
The Turkish Ministry of Health granted the compassionate
use of anti-IL-6 for TA patients and every patient planned
to undergo this treatment signed an informed consent
form. Therefore, this study was performed after the
approval of both the local ethical committee (approval
number: GO 18/266-01) and the Turkish Medicines and
Medical Devices Agency of the Turkish Ministry of Health
(approval number: 75642246-000-E.107089)
2.5. Statistical analysis
Statistical analysis was performed using SPSS 21.0 (IBM
Corp, Armonk, NY, USA). The values are expressed as
mean ± SD and median (min–max), unless indicated
otherwise. The Wilcoxon signed rank test was used to
compare the parameters whenever appropriate. P < 0.05
was considered as statistically significant.			
		
3. Results
Fifteen patients (86.7% females) who received at least 3
doses of monthly tocilizumab infusions and had available
follow-up data were included in the analysis. The median
(min–max) age of the patients was 35 (20–58) years
and the median disease duration from diagnosis was 24
(12–168) months. The median (min–max) follow-up for
tocilizumab therapy was 15 (3–42) months. The clinical
and demographic characteristics of the patients are
shown in Table 1. Before tocilizumab therapy, all patients
received corticosteroids and at least 1 conventional
immunosuppressive agent [12 (80%) patients received
methotrexate, 7 (46.7%) patients received intravenous
cyclophosphamide, and 4 patients received azathioprine,
leflunomide, or mycophenolate mofetil]. Also, 5 (33.3%)
patients received TNF-i before tocilizumab (Table 2).
The indications for tocilizumab therapy were as follows:
radiologically active disease in 6 patients (acute phase
reactants were normal in one of them) and clinically
active disease in 9 patients (5 of them were radiologically
stable and the other 4 patients had no radiological
imaging).
Tocilizumab was combined with methotrexate in 8
patients and in 1 patient with leflunomide. There was a
significant decrease in median (min–max) ESR [26 (5–119)
mm/h vs. 3 (2–49) mm/h, P = 0.02], CRP [39.8 (2.4–149.0)
mg/L vs. 7.9 (0–92.9) mg/L, P = 0.017], and patient global
VAS assessment [50 (0–90) vs. 30 (0–60), P = 0.027] after
tocilizumab. In 8 patients, ESR and CRP levels were in the
normal range at the last follow-up visit. During follow-up,
tocilizumab was ceased in 2 patients due to ineffectiveness
in 1 patient (P5) and activation of accompanying
ankylosing spondylitis in the other (P6). Control vascular
imaging studies after tocilizumab therapy were available
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Table 1. The clinical and demographic characteristics of the TA patients.
Patient no.

Age/ sex

Age at diagnosis

Disease duration
(months)

Type of vascular
involvement*

Comorbidity

1

57/F

53

48

2a

Hypothyroidism

2

40/M

31

72

2a, P(+)

IBD, EpA

3

47/F

37

96

2b

AS, OP

4

25/F

20

36

5, P(+)

HT

5

55/F

53

12

5

HT, RA

6

40/F

36

12

5

HT, AS

7

30/F

27

12

2b

HT

8

28/F

23

48

2b, C(+)

AVR

9

52/F

35

168

5

-

10

43/F

40

24

5, P(+)

HT

11

31/F

23

84

5, P(+)

HT

12

31/F

29

24

5

HT

13

59/F

58

12

5

OP

14

49/F

46

12

5

HT

15

24/M

20

24

2a, P(+)

-

F: Female, M: Male, P: Pulmonary involvement, C: Coronary involvement, IBD: Inflammatory bowel diseases,
EpA: Enteropathic arthritis, AS: Ankylosing spondylitis, HT: Hypertension, RA: Rheumatoid arthritis, AVR:
Aortic valve replacement, OP: Osteoporosis.
*According to the angiographic findings, TA patients were classified into 5 categories [16].

for 9 patients, while 8 patients were radiologically stable
and regression was seen in 1 patient compared to the last
imaging before tocilizumab. However, 4 radiologically
stable patients had CRP levels above the upper limit of
normal (another patient (P2) who was radiologically stable
but had increased acute reactants had concomitant active
AS). The mean daily dose of prednisone (or its equivalent)
at the first tocilizumab administration was 16.2 (9.1) mg/
day while the mean dosage at last follow-up was 7.1 (3.8)
mg/day, showing that there was a significant decrease
in glucocorticoid dosage after tocilizumab (P = 0.001).
During the follow-up, no serious adverse events such as
severe infections, gastrointestinal perforations, or infusion
related reactions occurred. We did not observe leukopenia
or neutropenia in any of the patients. There were minor
nonspecific side effects in 3 patients (malaise in 1 patient,
leg swelling in 1 patient, and dizziness in another patient)
without causing drug cessation.
4. Discussion
This study is one of the largest series evaluating the effect
of tocilizumab therapy in refractory TA patients in real life.
Our findings supported the effectiveness of tocilizumab
in the treatment of refractory TA without major adverse
events. In most patients, acute phase reactant levels were
decreased and follow-up imaging findings were stable.

Previously, several case reports and observational
studies done with small groups of patients reported
the efficacy and safety of tocilizumab in refractory TA,
including the patients unresponsive to TNF-i [7–15].
Recently, Decker et al. published 4 cases and an updated
literature review on the tocilizumab efficacy and safety
in patients with TA [17]. In this literature review, among
105 patients, most cases were refractory and 90 patients
(85.7%) had an initial clinical meaningful response
within 3 months. Among these patients, 17 (77%) of 22
patients who were previously treated with TNF-i had
clinical improvement with tocilizumab. A corticosteroid
dose reduction was achieved in 75 of the 83 patients
(90.4%). The CRP and ESR levels at the end of follow-up
were reduced compared to the initiation of tocilizumab
treatment. Radiological improvement was noted in 43
of the 66 patients (65.2%). In that study, only 7 patients
were considered to have relapse in a median treatment
duration of 12 months [17]. Recently, the efficacy and
safety of tocilizumab (162 mg/week subcutaneously) was
investigated in a randomized, double-blind, placebocontrolled, and phase-3 trial (the TAKT study) from Japan
[18]. For inclusion, patients had to be receiving a stable
glucocorticoid dosage at least twice the dose at relapse and
be in remission for 1 week. Thirty-six patients with TA
were randomized 1:1 to receive weekly tocilizumab (162
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Steroid
dosage

CYC, MTX

AZT, MTX

CYC,

MMF

CYC, MTX

11

12

13

14

15

Pred. 20
mg/ad
Pred. 30
mg/ad
Pred. 5
mg/day
MPZ 6
mg/day
Pred. 40
mg/day

16.00

5.00

42.00

7.00

6

12

35

103

119

26

68

11

24

75

34

-

-

80/70/60

50/70/30

50/80(80

70/60/70

40/70/60

40/60/30

90/90/90

10/30/40

0/0/0

31.70 0/0/10

8.6

39.8

2.4

2.7

16.7

63.7

85.1

149.0 70/50/70

28.1

76.1

42.7

19.6

81.70 -

42.80 0/20/20

BTA:
Progression
MRA:
Progression
MRA:
Stable
BTA:
Stable
MRA:
Progression
BTA:
Progression
27

7

3

3

6

10

42

15

2.00

3.00

2.00

2.00

2.00

23.00

12.00

2.00

BTA:
21
Progression

30.00
2.00

5

20.00

28

MRA:
Stable

20

12.00

49.00

3.00

7.90

10.50

1.00

5.10

1.90

1.20

16.20

37.50

1.70

1.70

80.00

16.50

18.10

92.90

2.00

Follow-up
ESR CRP
duration
mm/h mg/L
(months)

MRA:
3
Stable
MRA:
34
Stable
MRA:
18
Progression

VAS (0–100)
ESR
CRP
(Pain/fatigue/ Imaging
mm/s mg/L
pt. global)

After tocilizumab therapy

30/30(30

20/50/20

30/60/30

Pred. 12.5/day

MPZ 4 mg/day

-

Pred. 15 mg/ad

Pred. 15 mg/ad

-

Pred. 5 mg/ad

10/0/5

60/60/60

50/50/50

40/70/60

10/20/30

*Switched to
adalimumab
*Switched to
adalimumab

Outcome/
adverse
events

MRA:
Stable
MRA:
Stable

Leg swelling

MRA:
Fatigue
Stable
CTA:
Stable
MRA:
Dizziness
Stable
CTA:
Regression
MRA:
Stable

CTA:
Stable

MRA:
Stable

VAS (0–100)
(Pain/fatigue/ Imaging
pt. global)

PS 500 mg/month 0/0/0

Pred. 30 mg/ad

Pred. 30 mg/ad

MPZ 4 mg/day

Pred. 20 mg/ad

MPZ 12 mg/ad

Pred. 5 mg/day

Pred. 15 mg/ad

Steroid dosage

CYC: Cyclophosphamide, MTX: Methotrexate, SSZ: Sulfasalazine, LEF: Leflunomide, MMF: Mycophenolate Mofetil, AZT: Azathioprine, PS: Pulse steroid, IFX: Infliximab, ETN:
Etanercept, ADA: Adalimumab,
Pred.: Prednisolone, MPZ: Methylprednisolone, ad: on alternate days, MRA: Magnetic resonance angiography, CTA: Computed tomography angiography.
*Tocilizumab was switched to adalimumab in 2 patients, due to ineffectiveness in P5 and the activation of accompanying ankylosing spondylitis in P6.

CYC, MTX

-

Pred. 15
mg/ad
CYC, MTX,
Pred. 10
SSZ, IFX, ADA mg/day
CYC, SSZ,
MPZ 32
MTX, PS, ETN mg/ad
CYC, MTX,
Pred. 30
LEF, IFX, ADA mg/ad
MPZ 16
MMF
mg/day
Pred. 40
MTX, PS, IFX
mg/ad
Pred. 40
MTX, PS, IFX
mg/ad
PS 500
MTX, PS
mg/month
Pred. 40
CYC. MTX
mg/ad

MTX

10

9

8

7

6

5

4

3

2

1

Patient Previous
no
treatments

Before tocilizumab therapy

Table 2. The parameters of disease activity before and after tocilizumab therapy.
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mg/week subcutaneously) or its placebo. In both groups,
prednisone was tapered by 10%/week from week 4. The
primary endpoint was time to relapse based on the signs
and symptoms of TA without imaging evaluation. The
primary endpoint was not met in this study. However, a
treatment difference suggesting favour for tocilizumab was
observed in the per-protocol set sensitivity analysis and
secondary endpoints. However, the results of this study
should be interpreted keeping in mind that it includes
only refractory TA patients and a low number of patients
[18]. The responses to tocilizumab therapy in our study are
consistent with the previous reports in the literature. There
was a significant decrease in glucocorticoid dosage and
ESR and CRP levels, and most of the patients’ radiological
findings were stable after tocilizumab therapy. Decker et
al. reported that 18 (18%) out of 101 patients had adverse
effects with tocilizumab therapy (10 infections, 5 cytopenia,
6 hepatitis, 1 pancreatitis, 1 cutaneous rash, and 1 breast
cancer) and 7 (7%) patients’ therapies were stopped due to
the adverse effects [17]. In our study, tocilizumab was well
tolerated by all of the patients. Minor side effects which
were nonspecific and did not cause drug cessation were
observed in 3 patients. Tocilizumab therapy was switched
due to ineffectiveness in 1 patient and in another due to
the activation of accompanying ankylosing spondylitis.
Although we reported a good clinical and radiological
response in refractory TA patients with tocilizumab, our
results should be evaluated with caution. Firstly, this was
a retrospective study with a limited number of patients.

Secondly, we used the clinical and laboratory parameters
to define the disease activity. Evaluation of the disease
activity of TA is still challenging. Previous studies showed
a progression of vascular lesions and the presence of
histologically active disease in half of the patients despite
clinical and laboratory remissions [19,20]. Thirdly, TA is
generally a slowly progressive disease and the progression
rates of radiological findings are variable [1,19]. Therefore,
although we did not document radiological progression of
any patients, treatment duration in our study may not be
sufficient to make a final conclusion.
Increasing importance of IL-6 in the pathogenesis of
TA promises the use of tocilizumab in refractory TA. Our
results support the clinical effectiveness of tocilizumab in
this patient group. However, long standing studies with
sufficient numbers of patients are needed to document the
effectiveness and safety of tocilizumab.
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